Atrys Health SA (ES:ATRY) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atrys Health SA has reported a strong first half in 2024, with revenues increasing by 5% to 107.4 million euros and adjusted EBITDA rising by 24.6% to 25.3 million euros. The company attributes its growth to advancements in all business areas, especially oncology, and is on track to meet its annual guidance of 220-224 million euros in turnover and 47-49 million in adjusted EBITDA. Significant growth in the Latin American market and the expansion of medical oncology centers in Mexico are highlighted as key contributors to Atrys’ financial success.
For further insights into ES:ATRY stock, check out TipRanks’ Stock Analysis page.